Compugen Ltd. (NASDAQ:CGEN) Stock Has Consensus Target Price of $5.00

Compugen Ltd. (NASDAQ:CGEN) has received a consensus recommendation of “Buy” from the five brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $5.00.

Several equities research analysts have recently issued reports on CGEN shares. HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Compugen in a research report on Monday, October 12th. Weiss Ratings restated a “hold (c-)” rating on shares of Compugen in a report on Tuesday, November 3rd.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC raised its position in Compugen by 12.1% in the first quarter. Renaissance Technologies LLC now owns 1,632,988 shares of the biotechnology company’s stock valued at $3,478,000 after purchasing an additional 176,088 shares during the period. WINTON GROUP Ltd boosted its position in shares of Compugen by 26.0% in the second quarter. WINTON GROUP Ltd now owns 197,110 shares of the biotechnology company’s stock worth $422,000 after buying an additional 40,614 shares during the period. Joel Isaacson & Co. LLC boosted its position in shares of Compugen by 291.7% in the third quarter. Joel Isaacson & Co. LLC now owns 47,000 shares of the biotechnology company’s stock worth $112,000 after buying an additional 35,000 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of Compugen in the second quarter valued at about $110,000. Finally, Glenmede Trust Co. NA grew its stake in shares of Compugen by 187.5% in the first quarter. Glenmede Trust Co. NA now owns 34,500 shares of the biotechnology company’s stock valued at $73,000 after buying an additional 22,500 shares in the last quarter. 12.22% of the stock is owned by hedge funds and other institutional investors.

Compugen Stock Performance

CGEN opened at $2.09 on Thursday. The firm has a 50 day moving average price of $2.22 and a 200 day moving average price of $2.29. The company has a market cap of $197.62 million, a PE ratio of 5.36 and a beta of 2.85. Compugen has a 1 year low of $1.43 and a 1 year high of $3.23.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Monday, November 9th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. Compugen had a net margin of 47.90% and a return on equity of 39.30%. The firm had revenue of $3.82 million for the quarter, compared to analysts’ expectations of $1.28 million. During the same period in the previous year, the company posted ($0.07) earnings per share. On average, sell-side analysts predict that Compugen will post -0.28 earnings per share for the current year.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is an Israeli clinical-stage biotechnology company focused on discovering and developing novel therapeutic and drug targets for cancer and other diseases. The company uses computational biology and artificial intelligence-based approaches to identify previously unrecognized biological mechanisms and translate them into potential medicines. Compugen’s research has primarily centered on immuno-oncology, with an emphasis on regulating immune responses within the tumor microenvironment.